This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (81)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Results of a Large Double-blind Trial

Stephen Sontag, MD; Malcolm Robinson, MD; Richard W. McCallum, MD; Kenneth W. Barwick, MD; Ronald Nardi, PhD

Arch Intern Med. 1987;147(8):1485-1491.

Abstract
• In a multicenter, double-blind trial, 284 patients with gastroesophageal reflux disease were evaluated before, during, and after six weeks of treatment with either placebo or ranitidine (150 mg twice daily). Randomization resulted in two comparable patient groups. Ranitidine treatment was significantly more effective than placebo treatment in decreasing the frequency and the severity of heartburn during both daytime and nighttime assessment periods. There was a significant correlation between improvement in heartburn symptoms and decrease in anatacid consumption; hence, patients receiving ranitidine consumed significantly fewer antacid tablets. Among patients with endoscopic esophagitis at baseline, the overall change in endoscopic classification after six weeks of therapy was significantly better for the ranitidine-treated patients. The ranitidine-treated group had less evidence of erosions and ulcerations as well as greater healing. There were no differences between the groups with respect to changes in esophageal mucosal sensitivity to acid perfusion or changes in histologic grading of esophageal mucosal biopsy specimens. The ranitidine safety profile was similar to that of previous studies. We conclude that, in patients with gastroesophageal reflux disease, ranitidine therapy, 150 mg twice daily, markedly reduced the heartburn symptoms of reflux disease and significantly improved the endoscopic appearance of the esophageal mucosa.

(Arch Intern Med 1987;147:1485-1491)

Author Affiliations
USA Glaxo Gastroesophageal Reflux Study Group

From the Ambulatory Care Unit, Hines (Ill) Veterans Administration Hospital (Dr Sontag); Department of Medicine, Oklahoma City Clinic (Dr Robinson); Section of Gastroenterology (Dr McCallum) and Department of Pathology (Dr Barwick), Yale University School of Medicine, New Haven, Conn; and Glaxo Inc, Research Triangle Park, NC (Dr Nardi).

Footnotes
Accepted for publication April 12, 1987.

Reprint requests to Division of Gastroenterology, Box 145, University of Virginia Medical Center, Charlottesville, VA 22908 (Dr McCallum); and to Ambulatory Care Unit, Hines (Ill) Veterans Administration Hospital, Hines, IL 60141 (Dr Sontag).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials
Sharma et al.
Gut 2004;53:iv58-iv65.
ABSTRACT | FULL TEXT  

Health Care Utilization After Medical and Surgical Therapy for Gastroesophageal Reflux Disease: A Population-Based Study, 1996 to 2000
Khaitan et al.
Arch Surg 2003;138:1356-1361.
ABSTRACT | FULL TEXT  

Effectiveness and Costs of Omeprazole vs Ranitidine for Treatment of Symptomatic Gastroesophageal Reflux Disease in Primary Care Clinics in West Virginia
Kaplan-Machlis et al.
Arch Fam Med 2000;9:624-630.
ABSTRACT | FULL TEXT  

Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease
DeVault et al.
Arch Intern Med 1995;155:2165-2173.
ABSTRACT  

Famotidine Relieves Symptoms of Gastroesophageal Reflux Disease and Heals Erosions and Ulcerations: Results of a Multicenter, Placebo-Controlled, Dose-Ranging Study
Sabesin et al.
Arch Intern Med 1991;151:2394-2400.
ABSTRACT  

Rationale and Efficacy of Conservative Therapy for Gastroesophageal Reflux Disease
Kitchin and Castell
Arch Intern Med 1991;151:448-454.
ABSTRACT